Raytheon Company RTN reported fourth-quarter 2019 earnings per share (EPS) of $3.16 from continuing operations, outpacing the Zacks Consensus Estimate of $3.11 by 1.6%. The bottom-line figure also improved 7.8% from the year-ago quarter’s $2.93 owing to operational improvements.
For 2019, Raytheon’s earnings came in at $11.92 per share, which surpassed the Zacks Consensus Estimate of $11.88 by 0.33%. The 2019 bottom-line figure also improved 17.4% from the prior-year number.
Raytheon's fourth-quarter sales of $7,842 million grew 6.5% on a year-over-year basis. The top line, however, fell short of the Zacks Consensus Estimate of $8,028 million by 2.3%.
For 2019, Raytheon generated sales of $29.18 billion, which marginally missed the Zacks Consensus Estimate of $29.35 billion by 0.58%. However, on a year-over-year basis, full-year sales improved 7.8%.
The company’s bookings totaled $12,058 million compared with $8,447 million in the year-ago quarter, reflecting a surge of 42.7%. Total backlog at the end of 2019 was $48.75 billion, up 14.9% from the previous year’s figure.
Total operating expenses increased 6.8% to $6,563 million. The company’s operating income of $1,279 million rose 5.4% year over year.
Raytheon Company Price, Consensus and EPS Surprise
Raytheon Company price-consensus-eps-surprise-chart | Raytheon Company Quote
Integrated Defense Systems: Sales at this segment grew 18% year over year to $1,981 million, driven by higher net sales from an international air and missile defense system program and an international missile defense radar program. Meanwhile, operating income in the reported quarter also grew 24% to $307 million from $247 million a year ago.
Intelligence, Information and Services: Sales at this segment totaled $1,742 million, higher than the year- ago level of $1,711 million by 2%. Operating income in the reported quarter also improved 3% to $149 million
from $144 million a year ago.
Missile Systems: Revenues at this segment grew 1% to $2,345 million from $2,317 million a year ago, owing to higher net sales on classified programs in 2019. Moreover, operating income improved 9% to $297 million from $273 million in the year-ago quarter.
Space and Airborne Systems: At this segment, revenues grossed $2,018 million that witnessed 7% growth from the year-ago quarter. This upside was driven by increased net sales from classified programs, Next Generation Overhead Persistent Infrared (Next Gen OPIR) program and tactical communication system programs. Also, operating income rose 6% to $278 million on higher volumes.
Forcepoint: This commercial cybersecurity segment generated net revenues of $177 million in the fourth quarter, up 2.9% from $172 million a year ago.
Moreover, operating income in the reported quarter surged 200% to $6 million from $2 million a year ago.
Raytheon ended 2019 with cash and cash equivalents of $4,292 million, up from $3,608 million as of Dec 31, 2018.
Long-term debt summed $3,261 million, as of Dec 31, 2019, down from $4,755 million, as of Dec 31, 2018.
Net cash inflow from operating activities amounted to $4,480 million in 2019 compared with $3,428 million in 2018.
Raytheon currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Recent Defense Releases
Teledyne Technologies Inc. TDY reported fourth-quarter 2019 adjusted earnings of $2.90 per share, which surpassed the Zacks Consensus Estimate of $2.76 by 5.1%. The bottom-line figure came above the guided range of $2.71-$2.76.
Lockheed Martin Corp. LMT reported fourth-quarter 2019 earnings of $5.29 per share, which surpassed the Zacks Consensus Estimate of $4.99 by 6%. The bottom line also improved 20.5% from $4.39 in the year-ago quarter.
Textron Inc. TXT reported fourth-quarter 2019 adjusted earnings of $1.11 per share, which surpassed the Zacks Consensus Estimate of $1.08 by 2.8%. The bottom line, however, declined 3.5% from $1.15 in the year-ago quarter.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Lockheed Martin Corporation (LMT) : Free Stock Analysis Report
Teledyne Technologies Incorporated (TDY) : Free Stock Analysis Report
Textron Inc. (TXT) : Free Stock Analysis Report
Raytheon Company (RTN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research